glutathione Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Glutathione (GSH) is an antioxidant in plants, animals, fungi, and some bacteria and archaea. Glutathione is capable of preventing damage to important cellular components caused by reactive oxygen species such as free radicals, peroxides, lipid peroxides, and heavy metals. It is a tripeptide with a gamma peptide linkage between the carboxyl group of the glutamate side chain and cysteine. The carboxyl group of the cysteine residue is attached by normal peptide linkage to glycine.   Wikipedia

Chemistry

  • SMILES: N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O
  • InChIKey: YPZRWBKMTBYPTK-BJDJZHNGSA-N
  • Mol. Mass: 612.64
  • ALogP: -3.88
  • ChEMBL Molecules:
    oxiglutatione  
    glutathione  
More Chemistry

Pharmacology

Alternative names

5-l-glutamyl-l-cysteinylglycine | deltathione | gamma-l-glutamyl-l-cysteinyl-glycine | glutathion | glutathione | glutathione disulfide | glutathione disulphide | glutathione-sh | glutathione sodium | gluthathione | glutinal | gsh | gssg | l-glutathione | liposomal glutathione | n-(n-gamma-l-glutamyl-l-cysteinyl)glycine | reduced glutathione

Organizations (83)

Research & Development (56)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (27)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (25)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (25)


 

Adenocarcinoma (Phase 2)

Biliary Tract Diseases (Phase 3)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Cardiovascular Diseases (Phase 3)

COVID-19 (Phase 2)

Cystic Fibrosis (Phase 3)

Dermatology (Phase 1)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

End Stage Liver Disease (Phase 3)

Fallopian Tube Neoplasms (Phase 3)

Glutathione (Phase 1)

Hamartoma (Phase 3)

HIV Infections (Phase 2)

Leukemia (Phase 2)

Liver Failure (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Neurotoxicity Syndromes (Phase 3)

Ovarian Neoplasms (Phase 3)

Pain (Phase 3)

Pancreatic Neoplasms (Phase 2)

Parkinson Disease (Phase 2)

Peripheral Nerve Injuries (Phase 3)

Persian Gulf Syndrome (Phase 1/Phase 2)

Reperfusion Injury (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 40
  • # of Trial Organizations: 56

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue